Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Pancreatic Neoplasms 9Neuroendocrine Tumors 8Small Cell Lung Carcinoma 7Biliary Tract Neoplasms 5Stomach Neoplasms 4Sarcoma 4Cholangiocarcinoma 4Ovarian Neoplasms 3Osteosarcoma 3Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Thyroid Neoplasms 2Neoplasm Metastasis 2Colorectal Neoplasms 2Carcinoma, Neuroendocrine 2Carcinoma, Hepatocellular 2Advanced Colorectal Cancer 2Triple Negative Breast Neoplasms 1Thyroid Carcinoma, Anaplastic 1Solid Tumor 1Sarcoma, Ewing 1Rhabdomyosarcoma 1Refractory Metastatic Digestive System Carcinoma 1Pulmonary Neuroendocrine Tumor 1Pancreatic cancer, adult 1Pancreatic Cancer Metastatic 1Neuroectodermal Tumors, Primitive 1NSCLC 1Lymphoma 1Locally Advanced Pancreatic Cancer 1

Interventions

Pemetrexed 14Carboplatin 13osimertinib 10Drug Therapy 9aflutinib 8Gefitinib 7Radiotherapy 6Docetaxel 6Cisplatin 6anlotinib 5Radiosurgery 5Paclitaxel 5pembrolizumab 4Vinorelbine 4Gemcitabine 4tislelizumab 3icotinib 3apatinib 3HM781-36B 3Erlotinib Hydrochloride 3toripalimab 2spartalizumab 2rezivertinib 2camrelizumab 2Tyrosine Kinase Inhibitors 2Thalidomide 2Surgical Procedures, Operative 2S 1 (combination) 2Platinum 2Immune Checkpoint Inhibitors 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × NSCLC × surufatinib × Clear all
NCT06414915 2024-05-16

Surufatinib Combined With Tislelizumab in Advanced Lung Cancer With Neuroendocrine Differentiation

National Cancer Center, China

Phase 2 Not yet recruiting
29 enrolled
Thoracic

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡